相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
Jiyun Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report
Chunhua Ma et al.
FRONTIERS IN ONCOLOGY (2020)
Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer Case series
Hong-Joon Shin et al.
MEDICINE (2019)
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
Yiming Zhao et al.
TARGETED ONCOLOGY (2019)
Leptomeningeal metastases in non-small-cell lung cancer
Haiying Cheng et al.
LANCET ONCOLOGY (2018)
1449PEfficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany
W M Brueckl et al.
ANNALS OF ONCOLOGY (2018)
Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice
Shi-rong Zhang et al.
ACTA PHARMACOLOGICA SINICA (2017)
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Sabine Schmid et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study
Akihiro Tamiya et al.
ANTICANCER RESEARCH (2017)
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Yang-Si Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
J. K. Won et al.
ANNALS OF ONCOLOGY (2015)
Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation
Jin-Ji Yang et al.
CLINICAL CANCER RESEARCH (2014)
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
S. Dearden et al.
ANNALS OF ONCOLOGY (2013)
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2013)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
Clinical predictors of metastatic disease to the brain from non small cell lung carcinoma: Primary tumor size, cell type, and lymph node metastases
Amol Mujoomdar et al.
RADIOLOGY (2007)
分享论文
